{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:06:04Z","timestamp":1785855964761,"version":"3.56.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Health Sciences"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    This study aimed to assess the impact of ten sessions of major ozone therapy on disease severity and ophthalmologic parameters in patients with fibromyalgia syndrome (FMS). This observational study was conducted in the Physical Medicine and Rehabilitation and Ophthalmology clinics of a tertiary healthcare facility. The study involved 30 patients diagnosed with FMS who underwent 10 weekly sessions of major ozone therapy. Symptom severity was measured before and after treatment using the Fibromyalgia Impact Scale (FIQ). The study assessed ophthalmic parameters, including visual acuity, spherical equivalent, astigmatism, axis, intraocular pressure, and central corneal thickness. Additionally, microvascular changes were examined using optical coherence tomography angiography (OCTA). Post-treatment, FIQ scores decreased significantly (before: 67.19\u2009\u00b1\u200914.02; after: 46.78\u2009\u00b1\u200911.46;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001), indicating a notable reduction in symptom burden. The mean intraocular pressure was measured at 15.25\u2009\u00b1\u20092.67 mmHg before treatment and 15.41\u2009\u00b1\u20093.55 mmHg after treatment, while central corneal thickness was recorded as 530.50\u2009\u00b1\u200919.35\u00a0\u03bcm and 531.50\u2009\u00b1\u200919.21\u00a0\u03bcm. Superficial capillary plexus foveal vascular density was found to be 14.98\u2009\u00b1\u20097.16% before treatment and 15.34\u2009\u00b1\u20097.62% after treatment. Best-corrected visual acuity remained 1.0\u2009\u00b1\u20090.0 in both assessments. Spherical equivalent was \u2212\u20090.05\u2009\u00b1\u20091.05 D pre-treatment and \u2212\u20090.01\u2009\u00b1\u20091.03 D post-treatment (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.380), and astigmatism was \u2212\u20090.64\u2009\u00b1\u20090.60 D and \u2212\u20090.64\u2009\u00b1\u20090.54 D (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.100). Foveal avascular zone area (0.333\u2009\u00b1\u20090.129 vs. 0.331\u2009\u00b1\u20090.133\u00a0mm\u00b2;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.732), total foveal retinal thickness (213 vs. 214\u00a0\u03bcm;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.253), and deep capillary plexus foveal vascular density (30.07\u2009\u00b1\u20098.44% vs. 30.18\u2009\u00b1\u20098.18%;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.786) also remained stable. No statistically significant differences were observed in anterior segment parameters, intraocular pressure, central corneal thickness, or retinal microvascular structures as measured by OCTA (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&gt;\u20090.05). Ten sessions of major ozone therapy effectively reduced symptom burden in FMS patients, though short-term changes in the anterior segment and retinal microvascular structures were not measurable. Ozone therapy may serve as a complementary and supportive approach alongside existing treatments for managing FMS.\n                  <\/jats:p>","DOI":"10.1007\/s00296-026-06145-w","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T13:01:05Z","timestamp":1779541265000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Major ozone therapy improves disease severity without affecting retinal microvascular parameters in fibromyalgia syndrome: an observational pre-post study"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6065-8002","authenticated-orcid":false,"given":"Burhan Fatih","family":"Kocyigit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9033-5095","authenticated-orcid":false,"given":"G\u00fcl\u015fah Ya\u015fa","family":"\u00d6zt\u00fcrk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0610-2422","authenticated-orcid":false,"given":"Duygu Topakta\u015f","family":"Emekli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3146-6577","authenticated-orcid":false,"given":"Eda","family":"Sahutoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,23]]},"reference":[{"key":"6145_CR1","doi-asserted-by":"publisher","first-page":"166","DOI":"10.5114\/reum\/201416","volume":"63","author":"EB Imane","year":"2025","unstructured":"Imane EB, Salma B, Samira R, Hajar EA, Salma Z, Bouchra A, Rachid B (2025) Insights into diagnosis and treatment of fibromyalgia among Moroccan rheumatologists: a cross sectional online survey. Reumatologia 63:166\u2013173. https:\/\/doi.org\/10.5114\/reum\/201416","journal-title":"Reumatologia"},{"key":"6145_CR2","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1007\/s10067-023-06778-3","volume":"42","author":"B Ghavidel-Parsa","year":"2023","unstructured":"Ghavidel-Parsa B, Bidari A (2023) The crosstalk of the pathophysiologic models in fibromyalgia. Clin Rheumatol 42:3177\u20133187. https:\/\/doi.org\/10.1007\/s10067-023-06778-3","journal-title":"Clin Rheumatol"},{"key":"6145_CR3","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s10067-022-06385-8","volume":"42","author":"BF Kocyigit","year":"2023","unstructured":"Kocyigit BF, Akyol A (2023) Coexistence of fibromyalgia syndrome and inflammatory rheumatic diseases, and autonomic cardiovascular system involvement in fibromyalgia syndrome. Clin Rheumatol 42:645\u2013652. https:\/\/doi.org\/10.1007\/s10067-022-06385-8","journal-title":"Clin Rheumatol"},{"key":"6145_CR4","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s00296-022-05267-1","volume":"43","author":"BF Kocyigit","year":"2023","unstructured":"Kocyigit BF, Sagtaganov Z, Yessirkepov M, Akyol A (2023) Assessment of complementary and alternative medicine methods in the management of ankylosing spondylitis, rheumatoid arthritis, and fibromyalgia syndrome. Rheumatol Int 43:617\u2013625. https:\/\/doi.org\/10.1007\/s00296-022-05267-1","journal-title":"Rheumatol Int"},{"key":"6145_CR5","doi-asserted-by":"publisher","first-page":"3562191","DOI":"10.1155\/2022\/3562191","volume":"2022","author":"W Shen","year":"2022","unstructured":"Shen W, Liu N, Ji Z et al (2022) Combining ozonated autohemotherapy with pharmacological therapy for comorbid insomnia and myofascial pain syndrome: a prospective randomized controlled study. Pain Res Manag 2022:3562191. https:\/\/doi.org\/10.1155\/2022\/3562191","journal-title":"Pain Res Manag"},{"key":"6145_CR6","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s00296-023-05504-1","volume":"44","author":"GY Ozturk","year":"2024","unstructured":"Ozturk GY, Kocyigit BF (2024) Healing refractory livedoid vasculopathy-related skin ulcers by ozone therapy: a case-based review. Rheumatol Int 44:369\u2013377. https:\/\/doi.org\/10.1007\/s00296-023-05504-1","journal-title":"Rheumatol Int"},{"key":"6145_CR7","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s10792-025-03497-3","volume":"45","author":"G \u00c7elik","year":"2025","unstructured":"\u00c7elik G, Kolda\u015f Do\u011fan \u015e, Bulut M, B\u00fcber H, Durmaz D (2025) Evaluation of ophthalmic vascular and neural structures in female patients with fibromyalgia syndrome and their relationship with disease severity. Int Ophthalmol 45:123. https:\/\/doi.org\/10.1007\/s10792-025-03497-3","journal-title":"Int Ophthalmol"},{"key":"6145_CR8","doi-asserted-by":"publisher","first-page":"103819","DOI":"10.1016\/j.pdpdt.2023.103819","volume":"44","author":"N Sevimli","year":"2023","unstructured":"Sevimli N, Kurna SA, \u015eilte Karamanl\u0131o\u011flu AD, \u00dcnl\u00fc \u00d6zkan F, Akta\u015f \u0130, \u00c7ak\u0131r M (2023) Characteristics of the retina and choroid in fibromyalgia patients and their correlation with disease severity and quality of life. Photodiagnosis Photodyn Ther 44:103819. https:\/\/doi.org\/10.1016\/j.pdpdt.2023.103819","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"6145_CR9","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s00296-025-05872-w","volume":"45","author":"DT Emekli","year":"2025","unstructured":"Emekli DT, Sahutoglu E, \u00d6zt\u00fcrk GY, Kocyigit BF (2025) Anterior segment alterations in fibromyalgia syndrome: a cross-sectional study on dry eye disease, meibomian gland dysfunction, and astigmatism. Rheumatol Int 45:120. https:\/\/doi.org\/10.1007\/s00296-025-05872-w","journal-title":"Rheumatol Int"},{"key":"6145_CR10","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1097\/ICO.0b013e318285c912","volume":"32","author":"K T\u00fcrkyilmaz","year":"2013","unstructured":"T\u00fcrkyilmaz K, T\u00fcrkyilmaz AK, Kurt EE, Kurt A, \u00d6ner V (2013) Dry eye in patients with fibromyalgia and its relevance to functional and emotional status. Cornea 32:862\u2013866. https:\/\/doi.org\/10.1097\/ICO.0b013e318285c912","journal-title":"Cornea"},{"key":"6145_CR11","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.survophthal.2020.05.006","volume":"66","author":"N Zdebik","year":"2021","unstructured":"Zdebik N, Zdebik A, Bogus\u0142awska J, Prze\u017adziecka-Do\u0142yk J, Turno-Kr\u0119cicka A (2021) Fibromyalgia syndrome and the eye-a review. Surv Ophthalmol 66:132\u2013137. https:\/\/doi.org\/10.1016\/j.survophthal.2020.05.006","journal-title":"Surv Ophthalmol"},{"key":"6145_CR12","doi-asserted-by":"publisher","first-page":"4129","DOI":"10.1167\/iovs.08-3083","volume":"50","author":"J Gallar","year":"2009","unstructured":"Gallar J, Morales C, Freire V, Acosta MC, Belmonte C, Duran JA (2009) Decreased corneal sensitivity and tear production in fibromyalgia. Invest Ophthalmol Vis Sci 50:4129\u20134134. https:\/\/doi.org\/10.1167\/iovs.08-3083","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"6145_CR13","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.semarthrit.2016.08.012","volume":"46","author":"F Wolfe","year":"2016","unstructured":"Wolfe F, Clauw DJ, Fitzcharles MA et al (2016) 2016 revisions to the 2010\/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum 46:319\u2013329. https:\/\/doi.org\/10.1016\/j.semarthrit.2016.08.012","journal-title":"Semin Arthritis Rheum"},{"key":"6145_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s002960000077","volume":"20","author":"S Sarmer","year":"2000","unstructured":"Sarmer S, Ergin S, Yavuzer GM (2000) The validity and reliability of the Turkish version of the fibromyalgia impact questionnaire. Rheumatol Int 20:9\u201312","journal-title":"Rheumatol Int"},{"issue":"3","key":"6145_CR15","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1167\/tvst.14.3.6","volume":"14","author":"TT Hormel","year":"2025","unstructured":"Hormel TT, Huang D, Jia Y (2025) Advances in OCT angiography. Transl Vis Sci Technol 14(3):6. https:\/\/doi.org\/10.1167\/tvst.14.3.6","journal-title":"Transl Vis Sci Technol"},{"key":"6145_CR16","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1007\/s00296-024-05662-w","volume":"44","author":"GY \u00d6zt\u00fcrk","year":"2024","unstructured":"\u00d6zt\u00fcrk GY, Emekli DT, Sahutoglu E, Kocyigit BF (2024) Evaluation of ophthalmic vascular and neuroretinal alterations in fibromyalgia syndrome: a cross-sectional comparative study. Rheumatol Int 44:1757\u20131765. https:\/\/doi.org\/10.1007\/s00296-024-05662-w","journal-title":"Rheumatol Int"},{"key":"6145_CR17","unstructured":"Medical Society for the Use of Ozone in Prevention and Therapy (2026) Medical society for the use of ozone in prevention and therapy \/ \u00c4rztliche Gesellschaft f\u00fcr Ozonanwendung in Pr\u00e4vention und Therapie. https:\/\/ozongesellschaft.de\/ozone-society.html#guidelines. Accessed 9 Mar 2026"},{"key":"6145_CR18","doi-asserted-by":"publisher","first-page":"e20475","DOI":"10.7717\/peerj.20475","volume":"13","author":"OF Tertemiz","year":"2025","unstructured":"Tertemiz OF, Ozduran E, Gursoy S, Hanci V, Kaygusuz K, Ozbek IC, Kur\u00e7alo\u011flu M, Sabuncu \u00dc (2025) Effect of major ozone autohemotherapy in fibromyalgia syndrome: a retrospective study. PeerJ 13:e20475. https:\/\/doi.org\/10.7717\/peerj.20475","journal-title":"PeerJ"},{"key":"6145_CR19","doi-asserted-by":"publisher","first-page":"R120","DOI":"10.1186\/ar2783","volume":"11","author":"RM Bennett","year":"2009","unstructured":"Bennett RM, Friend R, Jones KD, Ward R, Han BK, Ross RL (2009) The revised fibromyalgia impact questionnaire (FIQR): validation and psychometric properties. Arthritis Res Ther 11:R120. https:\/\/doi.org\/10.1186\/ar2783","journal-title":"Arthritis Res Ther"},{"key":"6145_CR20","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1089\/acm.2011.0739","volume":"19","author":"J Hidalgo-Tall\u00f3n","year":"2013","unstructured":"Hidalgo-Tall\u00f3n J, Men\u00e9ndez-Cepero S, Vilchez JS, Rodr\u00edguez-L\u00f3pez CM, Calandre EP (2013) Ozone therapy as add-on treatment in fibromyalgia management by rectal insufflation: an open-label pilot study. J Altern Complement Med 19:238\u2013242. https:\/\/doi.org\/10.1089\/acm.2011.0739","journal-title":"J Altern Complement Med"},{"key":"6145_CR21","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3233\/BMR-210368","volume":"36","author":"H Sucuo\u011flu","year":"2023","unstructured":"Sucuo\u011flu H, Soyda\u015f N (2023) Efficacy of ozone therapy as an add-on treatment in fibromyalgia: a randomized double-blind placebo-controlled study. J Back Musculoskelet Rehabil 36:357\u2013366. https:\/\/doi.org\/10.3233\/BMR-210368","journal-title":"J Back Musculoskelet Rehabil"},{"key":"6145_CR22","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s00296-025-05827-1","volume":"45","author":"A \u00dc\u015fen","year":"2025","unstructured":"\u00dc\u015fen A, \u00d6zcan DS, A\u011firman M, G\u00fcner H, Kocyigit BF (2025) Short- and medium-term effects of major ozone therapy on disease parameters in fibromyalgia syndrome: a retrospective study. Rheumatol Int 45:72. https:\/\/doi.org\/10.1007\/s00296-025-05827-1","journal-title":"Rheumatol Int"},{"key":"6145_CR23","doi-asserted-by":"publisher","first-page":"12586","DOI":"10.3390\/ijms232012586","volume":"23","author":"M Malatesta","year":"2022","unstructured":"Malatesta M, Cisterna B, Costanzo M (2022) Cellular and molecular mechanisms of ozone therapy: present knowledge and prospective applications. Int J Mol Sci 23:12586. https:\/\/doi.org\/10.3390\/ijms232012586","journal-title":"Int J Mol Sci"},{"key":"6145_CR24","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.3390\/cimb47121016","volume":"47","author":"K Napi\u00f3rkowska-Baran","year":"2025","unstructured":"Napi\u00f3rkowska-Baran K, Slawatycki J, Klemenska P, Treichel P, Najarian A, Margossian GA, Szota M, Plocka-Karpinska M, Ku\u0142akowski M (2025) Ozone as an immunomodulator-new therapeutic possibilities in the treatment of immunodeficiencies-a narrative review. Curr Issues Mol Biol 47:1016. https:\/\/doi.org\/10.3390\/cimb47121016","journal-title":"Curr Issues Mol Biol"},{"key":"6145_CR25","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s10753-020-01184-2","volume":"43","author":"APS Tartari","year":"2020","unstructured":"Tartari APS, Moreira FF, Pereira MCDS et al (2020) Anti-inflammatory effect of ozone therapy in an experimental model of rheumatoid arthritis. Inflammation 43:985\u2013993. https:\/\/doi.org\/10.1007\/s10753-020-01184-2","journal-title":"Inflammation"},{"issue":"3","key":"6145_CR26","doi-asserted-by":"publisher","first-page":"369","DOI":"10.6026\/973206300213369","volume":"21","author":"M Anthony","year":"2025","unstructured":"Anthony M, Komarraju S, Sathyanath D, Muralidharan S (2025) Ozone therapy: mechanisms and clinical applications \u2013 a review. Bioinformation 21(3):369. https:\/\/doi.org\/10.6026\/973206300213369","journal-title":"Bioinformation"},{"key":"6145_CR27","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s44337-025-00491-7","volume":"2","author":"E Ogut","year":"2025","unstructured":"Ogut E (2025) Mechanisms and therapeutic potential of ozone therapy in enhancing vasculogenesis and angiogenesis through growth factor activation and oxidative signaling pathways. Discov Med 2:240. https:\/\/doi.org\/10.1007\/s44337-025-00491-7","journal-title":"Discov Med"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-026-06145-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-026-06145-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-026-06145-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:39:20Z","timestamp":1783525160000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-026-06145-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,23]]},"references-count":27,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["6145"],"URL":"https:\/\/doi.org\/10.1007\/s00296-026-06145-w","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,23]]},"assertion":[{"value":"12 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Raw data can be shared if requested.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Open data sharing note"}},{"value":"The authors declare that no part of this manuscript has been copied, published, or submitted for publication elsewhere, in whole or in part.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}],"article-number":"106"}}